


Determination Imatinib Mesylate on Obelisc R Column

<https://sielc.com/determination-imatinib-mesylate-on-obelisc-r-column>

Chromatogram



Column:	Obelisc R
Column size:	4.6 × 150 mm, 5 µm
Mobile phase:	MeCN –50%
Buffer:	Ammonium Formate pH 3.0 - 50 mM
Flow rate:	1 ml/min
UV detection:	UV 270nm (MS-compatible mobile phase)
LOD:	0.003 ppm, based on the analysis of the sample 0.01 mg/ml injection volume 5 µl

Description

· High Performance Liquid Chromatography (HPLC) Method for Analysis of Imatinib mesylate .

Imatinib mesylate is classified as a signal transduction inhibitor with the chemical formula $C_{29}H_{31}N_7O$. It is an oral targeted therapy medication that is effective in treating chronic myeloid leukemia and metastatic gastrointestinal stromal tumors. Commercial versions of the drug were a topic of controversy when cancer specialists published a letter condemning the high costs of cancer treatments.

Imatinib mesylate can be retained on an Obelisc R column, which has both positive and negative ion-pairs embedded in the stationary phase, allowing for the fine tuning and separation of a wide range of compounds with different ionic properties. Imatinib mesylate can be determined isocratically using a simple MS-compatible mobile phase of acetonitrile (ACN) and water with Ammonium Formate (AmFm) buffer and detected by UV at 270nm, ELSD, CAD or LC/MS.

Method Parameters

Mobile Phase	MeCN -50%
Buffer	Ammonium Formate pH 3.0 – 50 mM
Flow Rate	1.0 ml/min
Detection	UV 270nm
Class of Compounds	Drug
Analyzing Compounds	Imatinib mesylate

HPLC Column Used

Obelisc R, 4.6 x 150 mm, 5 µm, 100 Å, dual ended

[Order this column at hplc-shop.de →](http://hplc-shop.de)